Valuation: XOMA Royalty Corporation

Market Cap 539M 471M 433M 404M 766M 51.35B 778M 5.2B 2.02B 25.24B 2.02B 1.98B 86.97B P/E 2026 *
54.7x
P/E 2027 * -860x
Enterprise Value 539M 471M 433M 404M 766M 51.35B 778M 5.2B 2.02B 25.24B 2.02B 1.98B 86.97B EV / Sales 2026 *
8.88x
EV / Sales 2027 * 10.3x
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
1 day+0.89%
1 week+2.02%
Current month+1.18%
1 month+3.12%
3 months+30.38%
6 months+53.63%
Current year+61.71%
1 week 42.01
Extreme 42.01
43
1 month 40.76
Extreme 40.76
43
Current year 22.29
Extreme 22.29
43
1 year 22.29
Extreme 22.29
43
3 years 13.48
Extreme 13.48
43
5 years 13.48
Extreme 13.48
43
10 years 3.96
Extreme 3.96
46.32
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-31
Director of Finance/CFO 42 2026-01-11
Chief Investment Officer 45 2023-01-02
Director TitleAgeSince
Chairman 70 2024-01-06
Director/Board Member 72 2012-12-12
Director/Board Member 52 2017-02-15
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

3,586 0.0296%
05-20Free

Chairman

3,586 0.0296%
05-20Free

Director

3,586 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.89%+2.02%+59.50%+144.04% 539M
+1.05%+3.22%+49.38%+69.37% 580M
-1.05%-1.39%-5.67%-17.49% 362M
+1.22%+11.74%-28.08%-40.20% 85.34M
Average +0.53%+3.87%+18.78%+38.93% 391.59M
Weighted average by Cap. +0.52%+2.16%+35.91%+69.02%

Financials

2026 *2027 *
Net sales 60.73M 53.09M 48.79M 45.48M 86.26M 5.78B 87.57M 586M 228M 2.84B 228M 223M 9.8B 52.5M 45.9M 42.18M 39.31M 74.57M 5B 75.7M 506M 197M 2.46B 197M 193M 8.47B
Net income 15.03M 13.14M 12.08M 11.26M 21.35M 1.43B 21.68M 145M 56.37M 704M 56.43M 55.22M 2.42B -900K -787K -723K -674K -1.28M -85.69M -1.3M -8.68M -3.37M -42.12M -3.38M -3.31M -145M
Net Debt - -
Logo XOMA Royalty Corporation
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Employees
14
Date Price Change Volume
26-07-02 US$43.00 +0.89% 137,659
26-07-01 US$42.62 +0.28% 124,640
26-06-30 US$42.50 +0.83% 199,999
26-06-29 US$42.15 0.00% 368,083
26-06-26 US$42.15 -0.12% 439,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
43.00USD
Average target price
39.00USD
Spread / Average Target
-9.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XOMA Stock